Scott Loughhead

Immunology and Microbiology · Life Sciences

10h-index1.5kcitations45works1.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(27), CAR-T cell therapy research(23), Virus-based gene therapy research(10), T-cell and B-cell Immunology(9), RNA Interference and Gene Delivery(8)

Publications45 total

Endothelial immune surveillance by intravascular antigen-experienced CD8+ T Cells: Uncovering an unrecognized role in antiviral defense 4519
The Journal of Immunology·2025Open Access
1027 A silicon membrane-based approach to deliver circular RNAs and engineer CAR-Ts with durable expression of membrane bound IL-2 and IL-12
Regular and Young Investigator Award Abstracts·2025Open Access
Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration
Molecular Carcinogenesis·2024· 5 citedOpen Access
Highly efficient non-viral delivery of macromolecules to unactivated human T cells using microfluidic transfection
The Journal of Immunology·2024
594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16<sup>+</sup>tumors treated with cell-based vaccine, SQZ-PBMC-HPV
Regular and Young Investigator Award Abstracts·2023Open Access
692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
693 SQZ-AAC-HPV-101: initial data from a phase I dose escalation/expansion study of SQZ-AAC-HPV, a red blood cell-based therapeutic cancer vaccine for HPV16+ solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
Investigational New Drugs·2023· 6 citedOpen Access
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ- PBMC-HPV) in HLA-A*02+ patients with HPV16+ Solid Tumors
Research Square (Research Square)·2022Open Access
321 Single mRNA constructs encoding multiple linked antigens allow for a multiantigen-specific CD8<sup>+</sup> T cell response driven by SQZ<sup>®</sup> eAPCs
Regular and Young Investigator Award Abstracts·2022Open Access
224 Generation of cell therapies for diverse applications using microfluidic Cell Squeeze<sup>®</sup>manufacturing technology
Regular and Young Investigator Award Abstracts·2022Open Access
638 COMMANDER-001: a phase 1/2, first-in-human, multicenter, open label study of SQZ-eAPC-HPV as monotherapy and with pembrolizumab in patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors (trial in progress)
Regular and Young Investigator Award Abstracts·2022Open Access
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice
Frontiers in Immunology·2022· 9 citedOpen Access
Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery
Immuno-Oncology Technology·2022· 12 citedOpen Access
Abstract CT241: ENVOY-001: A phase 1, multicenter, open-label study of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors
Cancer Research·2022
Abstract 2853: Co-delivery of antigen-encoding mRNA and signal 2/3 mRNAs to PBMCs by Cell Squeeze® technology generates SQZ™ eAPCs that prime CD8+T cells in a humanized mouse model
Cancer Research·2022
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity
The Journal of Immunology·2022· 21 citedOpen Access
48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors
Annals of Oncology·2021· 3 cited
156 RBC-derived, activating antigen carriers (SQZ AACs) prime potent T cell responses and drive tumor regression in vivo
Regular and Young Investigator Award Abstracts·2021· 1 citedOpen Access
211 SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines
Regular and Young Investigator Award Abstracts·2021Open Access
page 1 of 3Next →

Frequent Co-authors

Howard Bernstein(28), Armon Sharei(21), Ulrich H. von Andrian(11), Katarina Blagović(10), Carolyne K. Smith(8), Defne Yarar(8), Wade T. Iams(8), Michael S. Gordon(8), Nathan R. Miselis(8), Emrah Ilker Ozay(7), Ricardo Zwirtes(7), Julia Jennings(7), Katherine J. Seidl(7), Carmen Gerlach(6), Matthew G. Booty(6), Melissa Myint(6), Pablo Umaña(6), Joaquina Baranda(6), Matthew H. Taylor(6), Antonio Jimeno(6)